

FOI 3769

Treatment of Cancers

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

01/12/25 – 24/02/26

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	2
1.2 Apalutamide (Erleada)	4
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	2
1.4 Darolutamide (Nubeqa)	19
1.5 Enzalutamide (Xtandi)	66
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	35
1.8 Relugolix (Orgovyx, Ryeqo)	0
1.9 Olaparib (Lynparza)	1

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

01/12/25 – 24/02/26

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	11
2.2 Olaparib (Lynparza) for prostate cancer	0
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

01/12/25 – 24/02/26

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	0
3.2 Apalutamide (Erleada)	0
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	1
3.4 Darolutamide (Nubeqa)	2
3.5 Enzalutamide (Xtandi)	8

Q4. How many patients were treated with the following combinations in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

01/12/25 – 24/02/26

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel	9	0
4.2 Darolutamide (Nubeqa) monotherapy	10	2
4.3 Olaparib (Lynparza) + Abiraterone	0	0

Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

01/12/25 – 24/02/26

Name of medicine	Number patients treated
5.1 Abiraterone	0
5.2 Enzalutamide	0